Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs is inevitable. Although immune checkpoint blockades (ICBs) tar...

Full description

Bibliographic Details
Main Authors: Di Wu, Yangyang Liu, Xiaoting Li, Yiying Liu, Qifan Yang, Yuting Liu, Jingjing Wu, Chen Tian, Yulan Zeng, Zhikun Zhao, Yajie Xiao, Feifei Gu, Kai Zhang, Yue Hu, Li Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Immunology
Subjects:
neoantigens
cancer immunotherapy
immune checkpoint blockade
epidermal growth factor receptor
tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01366/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01366/full

Similar Items